Your browser doesn't support javascript.
loading
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.
Kuboki, Yasutoshi; Shimizu, Toshio; Yonemori, Kan; Kojima, Takashi; Kondo, Shunsuke; Koganemaru, Shigehiro; Iwasa, Satoru; Harano, Kenichi; Koyama, Takafumi; Lu, Vickie; Zhou, Xiaofei; Niu, Huifeng; Yanai, Tomoko; Garcia-Ribas, Ignacio; Doi, Toshihiko; Yamamoto, Noboru.
Afiliación
  • Kuboki Y; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Yonemori K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Kojima T; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Kondo S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Koganemaru S; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Iwasa S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Harano K; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Koyama T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Lu V; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, United States.
  • Zhou X; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, United States.
  • Niu H; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, United States.
  • Yanai T; Oncology Therapeutic Area Unit for Japan and Asia, Takeda Pharmaceutical Company Limited, Osaka, Japan.
  • Garcia-Ribas I; Oncology Early Development, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, United States.
  • Doi T; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Cancer Res Commun ; 2(11): 1426-1435, 2022 11.
Article en En | MEDLINE | ID: mdl-36970056
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias / Neutropenia Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2022 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias / Neutropenia Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2022 Tipo del documento: Article País de afiliación: Japón